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Abstract
AIM: To study whether high-sensitivity C-reactive pro-
tein (hs-CRP) measurement can aid the assessment of 
disease activity and glucocorticoid treatment in paedi-
atric inflammatory bowel disease (IBD).
METHODS: CRP levels were measured in 39 children 
with IBD undergoing colonoscopy [median age 12.8 years, 
Crohn’s disease (CD) n  = 20], in 22 other children with 
IBD followed for acute response to glucocorticoids, and 
in 33 paediatric non-IBD patients. When standard CRP 
level was below detection limit (< 5 mg/L), hs-CRP 
was analyzed.
RESULTS: Sixty-four percent (25/39) of the children 
with IBD undergoing colonoscopy displayed undetect-
able (< 5 mg/L) standard CRP levels. Of these, the hs-
CRP measurement could not differentiate between active 
(median, 0.2 mg/L, range, 0.007-1.37, n  = 17) or quies-
cent (0.1 mg/L, 0.01-1.89, n  = 8, P  = NS) disease. Pa-
tients with ileocolonic CD had higher CRP levels (14 mg/L, 
0.06-45, n  = 13) than patients with no ileal involvement 
(0.18 mg/L, 0.01-9, n  = 7, P  < 0.01) or ulcerative colitis 
(UC) (0.13 mg/L, 0.007-23, P  < 0.05). In children with 
active IBD treated with systemic glucocorticoids, the 
standard CRP was undetectable in 59% of the patients. 
The hs-CRP levels did not differ between patients that 
responded to steroid therapy and in non-responders. 
CONCLUSION: The measurement of hs-CRP did not 
prove useful in the assessment of disease activity or 
glucocorticoid treatment in paediatric IBD patients that 
had undetectable standard CRP.
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INTRODUCTION
C-reactive protein (CRP) is produced mainly in hepato-
cytes in response to acute phase stimuli such as inflam-
mation[1]. Its production is driven by circulating cytokines 
interleukin-6 (IL-6), IL-1β and tumor necrosis factor-α 
(TNF-α) originating from the inflamed tissues[2]. Genetic 
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variation, as well as age and sex affect the CRP levels[3]. 
As an acute phase response, CRP concentration may in-
crease rapidly up to 1000-fold[4].
CRP is commonly used to screen the activity of  chronic 
inflammatory diseases including inflammatory bowel dis-
ease (IBD). A study comparing CRP with clinical, endo-
scopic and radiologic findings in adults with IBD found 
an association between CRP, clinical disease activity, endo-
scopic inflammation and active histological inflammation[5]. 
Very recently however, a Norwegian group reported that 
only 29% of  adult patients with ulcerative colitis (UC) and 
75% of  patients with Crohn’s disease (CD) had elevated 
CRP levels at diagnosis[6]. In general, CD patients have 
higher CRP levels than patients with UC[7]. Still, also in CD 
a subgroup of  patients with clinically active disease present 
with low CRP. In two large clinical studies investigating new 
biological agents (CDP870 and natalizumab, respectively) 
in active CD, 60% of  the patients had CRP levels below 
10 mg/L and 25% below 3 mg/L[8,9]. 
In children, the data on CRP levels in active IBD is 
sparse. In a report from St Bartholomew’s Hospital, all 
paediatric patients with active CD (n = 26) had CRP val-
ues higher than 5 mg/L; of  patients with UC (n = 13), 
only 60% reached this cut-off  level[10].
High-sensitivity CRP (hs-CRP) assays measure CRP 
levels that were previously thought to be under the detec-
tion limit. In adult IBD patients, hs-CRP correlates with 
clinical disease activity in both UC and CD[11]. In children, 
this question has not been addressed. Therefore, in this 
pilot study we investigated the association between hs-
CRP and clinical and histological activity in paediatric IBD 
patients, and evaluated the effect of  glucocorticoid treat-
ment on the hs-CRP levels.
MATERIALS AND METHODS
Subjects
Study group Ⅰ: Paediatric IBD patients studied at the 
time of  colonoscopy: The first group was stratified from 
the consecutive paediatric IBD patients who underwent 
colonoscopies and agreed to participate in a follow-up 
study of  IBD patients at the Hospital for Children and 
Adolescents, Helsinki, Finland. Inclusion criteria to the 
study were (1) endoscopy-based diagnosis of  either UC 
or CD[12], and (2) age ≤ 18 years. Exclusion criteria were 
(1) previous surgery, and (2) any signs of  infection dur-
ing the preceding week.
The clinical characteristics of  the 39 patients are 
shown in Table 1. 20 patients were newly diagnosed. The 
other 19 patients received the following medication: 7 
patients were on 5-ASA, 3 patients on 5-ASA and gluco-
corticoid, 3 patients were on 5-ASA, glucocorticoid and 
azathioprine, 1 patient on 5-ASA and antibiotics, 1 patient 
on glucocorticoid and azathioprine, and 1 patient on glu-
cocorticoid, azathioprine, antibiotics and infliximab. Two 
patients had no medication due to quiescent disease and 1 
patient had no medication due to non-compliance.
The patients who underwent colonoscopy due to 
fresh disease, aggravation of  the symptoms or lack of  
response to conventional medication were defined as 
having clinically active disease according to Physicians 
Global Assessment (PGA). The patients who underwent 
colonoscopy in clinical remission according to PGA 
were categorized as having quiescent disease. 
Study group Ⅱ: Paediatric IBD patients followed up for 
acute response to glucocorticoids: The second group was 
a prospectively collected group of  22 children and adoles-
cents (median age 13.1 years, age range 3.5-18 years) with 
active IBD who were introduced to systemic glucocorti-
coid treatment due to active disease (Table 2) as described 
in detail[13]. Six patients in this study were recruited to the 
prospective extension of  the previous study[13]. Other in-
clusion criteria to the study were similar to group Ⅰ. The 
maintenance medication of  the patients at the onset of  
the steroid was: 5-ASA (n = 12), 5-ASA and azathioprine (n 
= 2), antibiotics (n = 4), no medication (n = 4). 
The glucocorticoid treatment was started either with 
peroral prednisolone (1 mg/kg per day, Prednisolone®, 
Leiras, Finland, n = 20) or budesonide (9 mg/d, Entocort®, 
AstraZeneca AB, Sweden, n = 2). The venous blood sam-
ples were drawn before the treatment was started and at 
the clinical follow-up visit at 2-4 wk after starting the glu-
cocorticoid. 
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Table 1  The background data of the paediatric IBD patients 
with CRP measurement at the time of the colonoscopy (n  = 
39)
UC 19
   M/F 10/9
   Pancolitis 16
   Left-sided disease   3
CD 20
   M/F 14/6
   Ileocolitis 13
   Colitis   7
Age (median, range, yr) 12.8 (1.9-18)
BMI (median, range, kg/m2) 18.40 (14.2-25)
Fresh diagnosis   20/39
Notably, all patients with Crohn’s disease presented with colitis. IBD: 
Inflammatory bowel disease; CRP: C-reactive protein; UC: Ulcerative 
colitis; CD: Crohn’s disease; BMI: Body mass index.
Table 2  The clinical characteristics of the 22 paediatric IBD 
patients followed for acute response to glucocorticoids
UC 14
   M/F   9/5
   Pancolitis 11
   Left-sided disease   3
CD   7
   M/F   5/2
   Ileocolitis   2
   Colitis   5
IC 1 male
Age (median, range, yr)             13.1 (3.5-18)
BMI (median, range, kg/m2) 16.9 (13.2-22.6)
Fresh diagnosis     7/22
IC: Indeterminate colitis.
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Clinician’s judgement (PGA) of  clinical improvement 
(decrease in stool rate and the amount of  blood in the 
stools, abating diarrhea) and decrease in the inflamma-
tory markers [erythrocyte sedimentation rate (ESR) and 
faecal calprotectin] by the time of  the follow-up visit (see 
above) was defined as therapeutic response. When these 
patients were recruited, no paediatric activity index for UC 
yet existed[14]. Acute (appearing during the first month of  
the treatment) glucocorticoid-related side effects (weight 
gain, development of  moon face, striae or acne) were reg-
istered[13]. The therapeutic response and the development 
of  side-effects were both graded with a two-grade scale 
(good/poor response, yes/no side effects)[15,16]. 
Controls: Thirty-three children and adolescents (median 
age 12.1 years, range 1.8-17.2 years) visiting the Outpa-
tient Clinic of  the Hospital for Children and Adolescents, 
Helsinki, Finland, due to gastrointestinal disorder (coeliac 
disease n = 5, loose stools n = 4, liver dysfunction n = 
3, pancreatic dysfunction n = 3, abdominal pain n = 2, 
Helicobacter gastritis n = 1, gastro-oesophageal reflux 
disease n = 1), growth follow-up n = 4, derangement in 
laboratory tests (hypercholesterolemia n = 3, leukopenia 
n = 1, sideropenia n = 1) or other reasons (obesity n = 1, 
fatigue n = 2, talassemia n = 1, and toe pain n = 1) served 
as non-IBD controls. Patients with acute infection, fever 
or trauma were excluded.
Histology
During the colonoscopies, routine biopsies were taken 
from the ileum, caecum, colon ascendens, transversum, 
descendens, sigma and rectum. The histological findings 
were graded by an experienced paediatric pathologist 
(R.K.) with a modified histology score originally devel-
oped for CD (Table 3)[17,18]. The score was calculated: 
(1) separately for each segment (max 15 points) and (2) 
adding the scores of  the caecum, colon ascendens, trans-
versum, descendens, sigma and rectum to obtain the total 
score for the colon (max 90 points). Eosinophils were 
taken into account when analysing the quantity of  the 
polymorphonuclear cells. Instead, lymphoid hyperplasia 
was omitted from the count, since it represents a normal 
variant. The presence of  granulomas was registered, but 
not calculated in the score.
Laboratory analyses
The venous blood samples were scheduled between 11 am 
and 3 pm. Blood count, standard CRP (detection limit 
5 mg/L), and ESR were analysed in a clinical laboratory. 
In patients with standard CRP levels under the detection 
limit, serum hs-CRP levels were measured. The hs-CRP 
analyses were performed with a human C-reactive protein 
Instant ELISA kit (Bender MedSystems GmbH, Vienna, 
Austria) that has an intra-assay coefficient of  variation 
(C.V.) of  6.9%, interassay C.V. of  13.1% and detection 
limit of  3 × 10-6 mg/L. Faecal calprotectin was quantified 
as previously reported[19].
Statistical analysis 
Mann-Whitney’s U test, Kruskal-Wallis test, Wilcoxon’s 
signed rank sum test, Fisher’s exact test and Spearman’s 
rank order correlation test were used when investigating 
associations between non-parametric variables. Statistical 
analyses were performed using SPSS by SPSS Inc. soft-
ware. P < 0.05 was accepted to indicate statistical signifi-
cance. Values are expressed as median (range) in the text.
Ethical considerations
The families were informed about the study, and a writ-
ten informed consent was obtained from the patient and 
their guardians. The study protocol was approved by 
the Ethics Committee for the Hospital for Children and 
Adolescents, University of  Helsinki. 
RESULTS
The CRP levels in paediatric IBD patients at the time of 
the colonoscopy
Standard CRP testing was undetectable (< 5 mg/L) in 
64% (25/39) paediatric IBD patients investigated at the 
time of  the colonoscopy. Of  the patients with standard 
CRP levels below the detection limit, hs-CRP was mea-
surable in all cases (Figure 1).
The median CRP level in the whole IBD group was 
0.4 mg/L (0.007-45 mg/L). In all IBD patients, either 
with a fresh (0.7 mg/L, 0.02-39) or existing (0.2 mg/L, 
0.007-45) diagnosis of  colitis, CRP levels were higher 
than in the control patients (P < 0.01, see below). How-
ever, in patients with standard CRP levels under the de-
tection limit of  5 mg/L, the hs-CRP measurement could 
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Table 3  The assessment of the histology score[17]
Epithelial damage
   0 Normal
   1 Focal pathology
   2 Extensive pathology
Architectural changes
   0 Normal
   1 Moderately (< 50%) disturbed
   2 Severely (> 50%) disturbed
Infiltration of mononuclear cells in the lamina propria
   0 Normal
   1 Moderate increase
   2 Severe increase
Infiltration of polymorphonuclear cells in the lamina propria
   0 Normal
   1 Moderate increase
   2 Severe increase
Infiltration of polymorphonuclear cells in the epithelium
   0 Normal
   1 If in surface epithelium
   2 If cryptitis
   3 If a crypt abscess present
Presence of erosion or ulcers
   0 No
   1 Yes
The number of biopsy specimens affected
   0 None
   1 < 33%
   2 33%-66%
   3 > 66%
The score was calculated separately for each segment.
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not stratify the patients according to disease activity 
(active disease 0.2 mg/L, 0.007-1.37, n = 17 vs quiescent 
disease 0.1 mg/L, 0.01-1.89, n = 8, P = NS). 
In CD patients, standard CRP was undetectable in 
45% (9/20) of  the patients, in UC in 84% (16/19) of  
the patients (P < 0.05). Patients with ileocolonic CD had 
clearly higher CRP levels (14 mg/L, 0.06-45, n = 13) 
than patients with CD colitis (0.18 mg/L, 0.01-9, n = 7, 
P < 0.01) whose CRP levels were similar to the patients 
with UC (0.13 mg/L, 0.007-23, P = NS). The CRP levels 
in CD patients were also higher in those presenting with 
granulomas (14 mg/L, 0.5-39, n = 9) than in those with-
out granulomas (0.5 mg/L, 0.01-45, n = 11, P < 0.05). 
However, patients with granulomas did not have signifi-
cantly more ileocolonic disease than colitis (P = 0.07). 
The correlations between CRP levels, inflammatory 
markers and histology score, and the median (range) of  
these variables are presented in Table 4. The CRP levels 
did not correlate with age or weight; however, boys had 
higher CRP levels (4.9 mg/L, 0.007-45, n = 24) than girls 
(0.2 mg/L, 0.01-14, n = 15, P < 0.05).
The CRP levels in the non-IBD controls
The median CRP level in the 33 non-IBD controls was 
0.03 mg/L (0.008-0.7 mg/L), significantly lower that in the 
above-mentioned group of  39 IBD patients (P < 0.001). 
In controls, the distribution of  age (12.1 years, 1.8-17.2), 
sex (20 males, 13 females) and weight (37 kg, 12.8-84.6) 
were comparable to the 39 IBD patients (P = NS). Unlike 
in the IBD patients, CRP in the control patients correlated 
with weight (r = 0.460, P < 0.01). The control patients in 
the highest hs-CRP quartile were admitted due to obesity 
(n = 1), chronic autoimmune hepatitis (n = 1), leukopenia 
(n = 1), hypercholesterolemia (n = 1), talassemia minor 
(n = 1), gastro-oesophageal reflux disease (n = 1), coeliac 
disease (n = 1) and growth follow-up (n = 1). 
The CRP levels in children with IBD during 
glucocorticoid therapy 
The median pre-treatment CRP level of  the 22 IBD pa-
tients starting peroral glucocorticoid therapy was 0.6 mg/L 
(0.01-39), similar to the level of  CRP in the 39 IBD pa-
tients undergoing colonoscopy (P = NS). At the onset 
of  the glucocorticoid treatment, the standard CRP levels 
were below the detection limit of  5 mg/L in 59% (13/22) 
of  the patients. After 2-4 wk of  treatment, the median 
level was 0.08 mg/L (0.004-60, P < 0.05). Of  the 13 pa-
tients whose hs-CRP was measured (standard CRP unde-
tectable), 7 patients responded well to the glucocorticoids; 
however the change in their hs-CRP levels during the 
glucocorticoid did not differ from those patients who had 
poor response (P = 0.16). The development of  glucocor-
ticoid-related side effects was not associated with serum 
CRP levels (data not shown). 
DISCUSSION
The aim of  our study was to analyse whether hs-CRP 
can improve the assessment of  disease activity in paedi-
atric patients with IBD. We measured CRP with standard 
and high-sensitivity methods in children and adolescents 
presenting with colitis, and studied the association with 
other inflammatory markers (ESR, faecal calprotectin, 
and white blood cell count) and with the histological ac-
tivity of  the inflammation in the gut. 
Even though CRP is commonly used as a marker of  
inflammatory activity in IBD patients, our findings sup-
port the concept that a significant number of  patients with 
active IBD present with low CRP levels[6,10]. Here, standard 
CRP was under the detection limit of  5 mg/L in 60% of  
the paediatric patients with active colitis. All patients with 
undetectable standard CRP had measurable hs-CRP levels 
but there was no cut-off  value for low CRP values with 
which to differentiate active and quiescent disease.
In this study all patients with CD presented with coli-
tis. Thereby, it was somewhat surprising that there was 
a clear difference in the CRP values between UC and 
CD, the latter presenting with higher values. However, 
high CRP values associated with ileocolonic CD and 
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Table 4  The median (range) levels of inflammatory markers 
and histology score and their correlation with the CRP levels 
in 39 paediatric patients with IBD
Median (range) Correlation with CRP
Inflammatory markers
   Calprotectin (n = 35) 690 µg/g (14-4400)   0.488b
   ESR (n = 37) 18 mm/h (2-97)   0.618d
   WBC (n = 38)  7.6 E9/L (3.2-17.4) -0.011
Histology score
   Ileum (n = 29)1   0 (0-15)   0.475a
   Caecum (n = 38)   4 (0-14) -0.036
   Ascendens (n = 34) 4.5 (0-13) -0.198
   Transversum (n = 36)    6 (0-15) -0.158
   Descendens (n = 39)    6 (0-15) -0.077
   Sigma (n = 35)    5 (0-14) -0.014
   Rectum (n = 38) 5.5 (0-14) -0.051
   Total colon (n = 32)  30 (0-74) -0.083
1The histology score of the ileum was positive in only one UC patient 
(with backwash ileitis), all the other positive scores are from CD patients. 
aP < 0.05, bP < 0.01, dP < 0.001. ESR: Erythrocyte sedimentation rate; WBC: 
White blood cell count.
100
10
1
0.1
0.01
0.001
5 mg/L
CRP (mg/L)
m
g/
L
Figure 1  The C-reactive protein (CRP) levels in the 39 paediatric inflam-
matory bowel disease (IBD) patients undergoing colonoscopy. 14 patients 
had measurable (> 5 mg/L) standard CRP levels, the high-sensitivity CRP (hs-
CRP) levels were analyzed in 25 patients that had undetectable standard CRP. 
For hs-CRP the detection limit is 3 × 10-6 mg/L. 
Patients with active disease
Patients with quiescent 
disease
Patients that had measurable 
standard CRP levels
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in CD colitis with no ileal involvement the CRP values 
were similar to UC. This is in contrast to previous stud-
ies in adults with IBD showing no difference between 
disease location and CRP levels in CD patients, or even 
opposing results - ileal disease associated with low CRP 
levels[6,20]. However, in our study we investigated also 
the association between CRP and histological activity 
of  the colonoscopy biopsies, and found that the CRP 
levels correlated only with the histological score of  the 
ileal biopsies, not with colonic inflammation. Studies 
in adults with CD have shown that an accumulation of  
intra-abdominal fat has been observed in CD patients, 
and that CRP levels correlate with radiological findings 
of  small bowel perienteric inflammation (increased fat 
density)[21,22]. Since CRP is expressed in human adipose 
tissue, our findings may reflect higher local CRP produc-
tion in the inflamed perienteric ileal region[23].
The association between granulomas and CRP levels 
in our study is a novel observation. In the literature, the 
evidence on the clinical significance of  granulomas in 
CD patients is conflicting. Some studies associate the 
presence of  granulomas with a more aggressive disease 
course, whereas others do not report any connection 
between granulomas and disease severity[24,25]. Recently, 
a study from the Children’s Hospital of  Philadelphia did 
not find a relationship between CRP levels and granulo-
mas, although the presence of  granulomas was associat-
ed with a more severe disease course[26]. The discrepancy 
between the CRP findings in these two studies could be 
explained by the fact that the patient populations differ, 
because the US study also included patients presenting 
granulomas only in the upper GI tract or terminal ileum. 
In an in vitro study, invasive Escherichia coli strains recov-
ered from CD lesions caused macrophages to secrete 
TNF-α[27]. It is intriguing to speculate that higher local 
production of  TNF-α in the granulomatous lesions of  
CD patients could explain the higher CRP levels associ-
ating with granulomas in our study. However, as yet the 
relationship remains elusive.
Only a few groups have studied the hs-CRP levels in 
IBD, and none of  them have concentrated on the treat-
ment-induced changes[11,28,29]. In this study, we additionally 
analysed a group of  children and adolescents with IBD that 
started peroral glucocorticoid therapy due to the activation 
of  the disease. In our small group of  patients however, the 
measurement of  hs-CRP did not provide any additional 
information as to the treatment of  these patients.
Limitations of  our study are the relatively small 
sample size, especially when the patients are divided into 
subgroups of  UC and CD. In addition, apart from in-
flammation, minor trauma, acute infection, obesity and 
the use of  NSAIDs, and genetic heterogeneity in the 
basal expression of  CRP may affect the hs-CRP levels[30]. 
However, all patients undergoing colonoscopy had nor-
mal BMI and did not have any clinical signs of  acute in-
fection. As the subjects are children, we cannot rule out 
the possibility of  minor bumps and bruises that might 
have affected the hs-CRP levels. Also, the possible intake 
of  NSAIDs was unfortunately not recorded.
In conclusion, our study reinforces the concept that a 
significant number of  paediatric patients with active IBD 
may present with CRP levels that are under the detection 
limit. Hs-CRP instead, was detectable in all the patients. 
Unfortunately, in this pilot study the measurement of  
hs-CRP levels in the patients that had undetectable stan-
dard CRP levels could not stratify the patients according 
to disease activity or response to treatment. 
ACKNOWLEDGMENTS
Ms. Sari Honkanen, Ms. Anne Nikkonen, Ms. Elsa Val-
tonen, Ms. Minna Kuurne-Koivisto, Ms. Anne Ramstadt 
are thanked for their excellent assistance and Professor 
Seppo Sarna for advising in the statistical analyses. 
COMMENTS
Background
C-reactive protein (CRP) is used to assess disease activity in diverse inflam-
matory disorders including inflammatory bowel disease (IBD). However, in IBD 
a significant number of patients present with low CRP levels despite clinically 
active disease. In paediatric patients with IBD the performance of CRP is an 
understudied area.
Research frontiers
High-sensitivity CRP (hs-CRP) measures CRP levels that were previously 
thought to be under the detection limit. In paediatric IBD, this kind of highly 
sensitive marker is needed for the detection of the presence of inflammation. 
Thus, the authors studied the performance of hs-CRP in paediatric IBD to see 
whether it improves the assessment of inflammation in these patients and/or 
associates with the response to glucocorticoid therapy.
Innovations and breakthroughs
Hs-CRP is a sensitive marker of inflammation that is used in various conditions 
(asthma, cardiovascular disease). In paediatric IBD, the performance of the hs-
CRP has not been studied previously. The authors show here that standard CRP 
test is negative in a considerable number of paediatric patients with active IBD 
and the routine measurement of CRP is thus not informative enough. Hs-CRP de-
tects low levels of CRP but disappointingly it does not help to distinguish children 
with active intestinal inflammation from those with quiescent disease or those 
responding to glucocorticoid treatment from non-responders. Interestingly, the 
levels of hs-CRP correlated with the presence of ileal inflammation.
Applications 
The determination of hs-CRP seems to be of minor aid in assessing the 
presence of inflammation in paediatric IBD. In ileal disease, however, hs-CRP 
correlates with the presence of histological inflammation, a finding warranting 
further studies.
Terminology
IBD comprising Crohn’s disease (CD) and ulcerative colitis is a chronic, relapsing 
and remitting disease of the gastrointestinal tract characterized by diarrhea, 
abdominal pain and weight loss. CRP is an acute phase protein produced by liver 
that is used in the diagnosis of inflammatory disorders.
Peer review
This clinical study has originality, is well designed and executed; the results are 
well presented and interpreted. Although this study shows a negative result, it 
has still provided valuable information on the CRP measurement in children IBD 
patients. One of the weaknesses is the small sample size of subgroup patients 
particularly CD patients in Table 2. It would strengthen the conclusion if more 
patients were included in this study.
REFERENCES
1 Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, 
receptors and role in inflammation. Clin Immunol 2005; 117: 
104-111
2 Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein 
as a marker for inflammatory bowel disease. Inflamm Bowel 
2905 June 21, 2010|Volume 16|Issue 23|WJG|www.wjgnet.com
 COMMENTS
Sidoroff M et al . C-reactive protein in paediatric IBD
Dis 2004; 10: 661-665
3 Ford ES, Giles WH, Myers GL, Rifai N, Ridker PM, Mannino 
DM. C-reactive protein concentration distribution among 
US children and young adults: findings from the National 
Health and Nutrition Examination Survey, 1999-2000. Clin 
Chem 2003; 49: 1353-1357
4 Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 
2004; 279: 48487-48490
5 Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zins-
meister AR, Sandborn WJ. Correlation of C-reactive protein 
with clinical, endoscopic, histologic, and radiographic activ-
ity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 
11: 707-712
6 Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn 
MH, Moum B. C-reactive protein: a predictive factor and 
marker of inflammation in inflammatory bowel disease. Re-
sults from a prospective population-based study. Gut 2008; 
57: 1518-1523
7 Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, 
Petrie A, Pepys MB. Serum levels of C-reactive protein in 
Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 
12: 351-359
8 Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, 
Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen 
OØ, Innes A. A randomized, placebo-controlled trial of cer-
tolizumab pegol (CDP870) for treatment of Crohn's disease. 
Gastroenterology 2005; 129: 807-818
9 Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, 
Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan 
S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutg-
eerts P. Natalizumab induction and maintenance therapy for 
Crohn's disease. N Engl J Med 2005; 353: 1912-1925
10 Beattie RM, Walker-Smith JA, Murch SH. Indications for 
investigation of chronic gastrointestinal symptoms. Arch Dis 
Child 1995; 73: 354-355
11 Zilberman L, Maharshak N, Arbel Y, Rogowski O, Rozen-
blat M, Shapira I, Berliner S, Arber N, Dotan I. Correlated 
expression of high-sensitivity C-reactive protein in relation 
to disease activity in inflammatory bowel disease: lack of 
differences between Crohn's disease and ulcerative colitis. 
Digestion 2006; 73: 205-209
12 Lennard-Jones JE. Classification of inflammatory bowel 
disease. Scand J Gastroenterol Suppl 1989; 170: 2-6; discussion 
16-19
13 Vihinen MK, Raivio T, Verkasalo M, Jänne OA, Kolho KL. 
Circulating glucocorticoid bioactivity during peroral gluco-
corticoid treatment in children and adolescents with inflam-
matory bowel disease. J Clin Gastroenterol 2008; 42: 1017-1024
14 Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue 
K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart 
AH, Griffiths AM. Development, validation, and evaluation 
of a pediatric ulcerative colitis activity index: a prospective 
multicenter study. Gastroenterology 2007; 133: 423-432
15 Vihinen MK, Kolho KL, Jänne OA, Andersson S, Raivio T. 
Circulating adiponectin as a marker for glucocorticoid-relat-
ed side effects in children and adolescents with inflammatory 
bowel disease. J Pediatr Gastroenterol Nutr 2009; 48: 504-506
16 Vihinen MK, Kolho KL, Ashorn M, Verkasalo M, Raivio T. 
Bone turnover and metabolism in paediatric patients with 
inflammatory bowel disease treated with systemic glucocor-
ticoids. Eur J Endocrinol 2008; 159: 693-698
17 D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx 
F, Rutgeerts P. Early lesions of recurrent Crohn's disease 
caused by infusion of intestinal contents in excluded ileum. 
Gastroenterology 1998; 114: 262-267
18 Sipponen T, Kärkkäinen P, Savilahti E, Kolho KL, Nuutinen 
H, Turunen U, Färkkilä M. Correlation of faecal calprotectin 
and lactoferrin with an endoscopic score for Crohn's disease 
and histological findings. Aliment Pharmacol Ther 2008; 28: 
1221-1229
19 Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotec-
tin remains high during glucocorticoid therapy in children 
with inflammatory bowel disease. Scand J Gastroenterol 2006; 
41: 720-725
20 Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. 
Clinically active Crohn's disease in the presence of a low 
C-reactive protein. Scand J Gastroenterol 2006; 41: 306-311
21 Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, 
Müller-Alouf H, Hafraoui S, Emilie D, Ectors N, Peuchmaur 
M, Cortot A, Capron M, Auwerx J, Colombel JF. Inflamma-
tory alterations in mesenteric adipose tissue in Crohn's dis-
ease. Gastroenterology 1999; 117: 73-81
22 Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV 
Jr, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG. 
Quantitative measurement and visual assessment of ileal 
Crohn's disease activity by computed tomography enterog-
raphy: correlation with endoscopic severity and C reactive 
protein. Gut 2006; 55: 1561-1567
23 Peyrin-Biroulet L, Chamaillard M, Gonzalez F, Beclin E, 
Decourcelle C, Antunes L, Gay J, Neut C, Colombel JF, Des-
reumaux P. Mesenteric fat in Crohn's disease: a pathogenet-
ic hallmark or an innocent bystander? Gut 2007; 56: 577-583
24 Heresbach D, Alexandre JL, Branger B, Bretagne JF, Cruch-
ant E, Dabadie A, Dartois-Hoguin M, Girardot PM, Jouanolle 
H, Kerneis J, Le Verger JC, Louvain V, Politis J, Richecoeur M, 
Robaszkiewicz M, Seyrig JA. Frequency and significance of 
granulomas in a cohort of incident cases of Crohn's disease. 
Gut 2005; 54: 215-222
25 Rubio CA, Orrego A, Nesi G, Finkel Y. Frequency of epi-
thelioid granulomas in colonoscopic biopsy specimens from 
paediatric and adult patients with Crohn's colitis. J Clin 
Pathol 2007; 60: 1268-1272
26 De Matos V, Russo PA, Cohen AB, Mamula P, Baldassano 
RN, Piccoli DA. Frequency and clinical correlations of granu-
lomas in children with Crohn disease. J Pediatr Gastroenterol 
Nutr 2008; 46: 392-398
27 Glasser AL, Boudeau J, Barnich N, Perruchot MH, Colombel 
JF, Darfeuille-Michaud A. Adherent invasive Escherichia coli 
strains from patients with Crohn's disease survive and rep-
licate within macrophages without inducing host cell death. 
Infect Immun 2001; 69: 5529-5537
28 Poullis AP, Zar S, Sundaram KK, Moodie SJ, Risley P, 
Theodossi A, Mendall MA. A new, highly sensitive assay 
for C-reactive protein can aid the differentiation of inflam-
matory bowel disorders from constipation- and diarrhoea-
predominant functional bowel disorders. Eur J Gastroenterol 
Hepatol 2002; 14: 409-412
29 Maharshak N, Arbel Y, Gal-Oz A, Rogowski O, Shapira I, 
Berliner S, Vered Y, Canaani J, Dotan I. Comparative analy-
sis of Bayer wide-range C-reactive protein (wr-CRP) and the 
Dade-Behring high sensitivity C-reactive protein (hs-CRP) in 
patients with inflammatory bowel disease. J Dig Dis 2008; 9: 
140-143
30 Kushner I, Rzewnicki D, Samols D. What does minor eleva-
tion of C-reactive protein signify? Am J Med 2006; 119: 166.
e17-166.e28
S- Editor  Wang YR    L- Editor  O'Neill M    E- Editor  Lin YP
2906 June 21, 2010|Volume 16|Issue 23|WJG|www.wjgnet.com
Sidoroff M et al . C-reactive protein in paediatric IBD
